[
  {
    "clause_index": 1,
    "start_char": 171,
    "end_char": 843,
    "original": "STRATEGIC ALLIANCE AGREEMENT Effective Date: April 17, 2017 THIS STRATEGIC ALLIANCE AGREEMENT (this \u201c Agreement \u201d), is entered into by and between Lion Biotechnologies, Inc., with a place of business located at 999 Skyway Road, Suite 150, San Carlos, CA 94070 (\u201c LBIO \u201d), and The University of Texas M. D. Anderson Cancer Center, with a place of business located at 1515 Holcombe Blvd., Houston, TX 77030 (\u201c MD Anderson \u201d), a member institution of The University of Texas System (\u201cSystem \u201d), as of the date set forth above (the \u201c Effective Date \u201d). MD Anderson and LBIO are hereinafter individually referred to as a \u201c Party \u201d and are collectively known as the \u201c Parties \u201d.",
    "ollama_generated": "STRATEGIC COOPERATION AGREEMENT Effective Date: April 17, 2017\n\nTHIS STRATEGIC COOPERATION AGREEMENT (this \"Agreement\"), is made and entered into by The University of Texas M. D. Anderson Cancer Center, with a place of business located at 1515 Holcombe Blvd., Houston, TX 77030 (\"MD Anderson\"), a member institution of The University of Texas System (\"System\"), and Lion Biotechnologies, Inc., with a place of business located at 999 Skyway Road, Suite 150, San Carlos, CA 94070 (\"LBIO\") on the date hereinafter referred to as the \"Effective Date\". For the purposes of this Agreement, either party shall be individually referred to as a \"Participant\" and collectively known as the \"Participants\".\n\nUnderstood that each Participant maintains its independent status and responsibilities, this Agreement outlines their mutual commitments and expectations for cooperation in areas mutually beneficial to both parties. The obligations set forth herein are minimum standards and do not diminish any Participant's rights or obligations under applicable law or other agreements.\n\nThe terms \"Party\" and \"Parties\" as used herein refer collectively to the University of Texas M. D. Anderson Cancer Center and Lion Biotechnologies, Inc., with each party retaining its own decision-making authority and independence in all matters not specifically addressed within this Agreement.",
    "contradiction_score": 0.038393277674913406,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 3,
    "start_char": 1365,
    "end_char": 1567,
    "original": "NOW, THEREFORE, in consideration of the mutual covenants contained herein, the receipt and sufficiency of which are hereby acknowledged, LBIO and MD Anderson hereby agree to be legally bound as follows:",
    "modified": "NOW, THEREFORE, with the understanding that neither party admits any legal obligation or liability beyond what is expressly stated herein, and acknowledging the mutual understandings contained within this agreement, LBIO and MD Anderson hereby undertake the following obligations:\n\nInstead of creating a binding agreement, this revised clause introduces an understanding between the parties that they are not admitting any legal obligation or liability beyond what is explicitly stated in the contract. This shifts the responsibility and potential for disputes towards explicit statements within the contract, rather than implying broader obligations.",
    "contradiction_score": 0.8051507472991943,
    "kept": true
  },
  {
    "clause_index": 8,
    "start_char": 3796,
    "end_char": 4474,
    "original": "1.4 Dispute Resolution . Decisions regarding Study design, changes and/or additions to the initially-agreed Protocols must be unanimous, with each Party exercising one vote each, and in the absence of such unanimity the status quo shall be maintained. For all other matters before the JSC, a unanimous decision, with each Party exercising one vote, is required\u037e provided, that, if unanimity cannot be achieved regarding such other matters, then LBIO\u2019s chief executive officer may make the decision on behalf of the JSC, provided that LBIO\u2019s chief executive officer will first make a good faith effort to consult with a designated executive at MD Anderson to resolve such matter.",
    "ollama_generated": "1.4 Dispute Resolution. When it comes to modifications in the Study design, changes to, or additions of Protocols beyond the initially agreed ones, the Parties will aim for consensus, each having one vote. In cases where consensus is not reached, the existing conditions shall be preserved. For all other matters falling under the jurisdiction of the Joint Steering Committee (JSC), a unanimous decision, with each Party exercising one vote, is necessary; however, if a unanimous decision cannot be attained on these matters, LBIO's chief executive officer shall have the authority to make the final decision. Before making such a decision, LBIO\u2019s chief executive officer will make a good-faith attempt to consult with an appropriate executive at MD Anderson in an effort to resolve the matter jointly. In other words, while unanimity is preferable for all decisions, when it cannot be achieved, LBIO's CEO can take action as the final arbiter, only after trying to collaborate with a designated executive at MD Anderson first.",
    "contradiction_score": 0.028067706152796745,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 19,
    "start_char": 9380,
    "end_char": 11621,
    "original": "(a) MD Anderson shall, and shall cause each of its employees, agents, contractors, and subcontractors performing Research activities or other obligations under this Agreement, including the Principal Investigator (collectively, \u201c Representatives \u201d) to, conduct such activities, and  use, store and handle all materials used in the performance of activities under this Agreement and each Study Order, or cause the same to be done, in accordance with (i) all applicable laws, regulations, and guidelines, including, to the extent applicable, the Federal Food, Drug, and Cosmetic Act (\u201c FFCDA \u201d)\u037e the anti-kickback and related provisions of the Social Security Act\u037e the Public Health Services Act\u037e the regulations promulgated by the Food and Drug Administration (\u201c FDA \u201d), including 21 C.F.R. Parts 50, 56, and 58, and, with respect to clinical Studies, the requirements of the Statement of Investigator, FDA Form 1572 (as described in 21 312.53), the terms of which are incorporated by reference into any Study Order pertaining to a clinical Study (and the Principal Investigator for any such clinical Study shall complete, sign, and deliver a Form 1572 to LBIO prior to the commencement of such Study)\u037e the United States Health Insurance Portability and Accountability Act of 1996, as amended by the HITECH Act, including the Standards for Privacy of Individually Identifiable Health Information\u037e the EU Data Protection Directive\u037e and all other applicable privacy, security and data protection laws (collectively, this sub-clause (i), \u201c Laws \u201d), and, as applicable, the quality standards of \u201c Good Clinical Practice \u201d (which term shall mean generally accepted good clinical practices including those set out in the current version of the Declaration of Helsinki and the International Conference on Harmonization Guidelines for Good Clinical Practice in force from time to time and FDA\u2019s most recent guidance and regulations concerning current Good Clinical Practice), (ii) the provisions of this Agreement (including each applicable Study Order and Protocol), and (iii) all written instruction from LBIO, as well as MD Anderson\u2019s internal policies and procedures to the extent they do not conflict with the foregoing subsections (i) and (ii).",
    "ollama_generated": "(a) LBIO grants MD Anderson the discretion to, and expects each of its employees, agents, contractors, and subcontractors involved in Research activities or other obligations under this Agreement (hereafter referred to as \"Representatives\") to, conduct such activities and manage all materials used in the performance of activities under this Agreement and each Study Order. However, they are expected to do so in accordance with:\n\n(i) All applicable laws, regulations, and guidelines, including, where relevant, the Federal Food, Drug, and Cosmetic Act (\"FFCDA\"), the anti-kickback and related provisions of the Social Security Act, the Public Health Services Act, the regulations promulgated by the Food and Drug Administration (\"FDA\"), such as 21 C.F.R. Parts 50, 56, and 58, and, with respect to clinical Studies, the requirements of the Statement of Investigator, FDA Form 1572 (as described in 21 CFR 312.53), whose terms are incorporated by reference into any Study Order pertaining to a clinical Study (and it is the responsibility of the Principal Investigator for any such clinical Study to complete, sign, and deliver a Form 1572 to MD Anderson prior to the commencement of such Study). Additionally, they should comply with all applicable privacy, security, and data protection laws, including but not limited to the United States Health Insurance Portability and Accountability Act of 1996, as amended by the HITECH Act, the EU Data Protection Directive, and any other relevant laws (collectively, this sub-clause (i), \"Laws\"). In cases where the quality standards of \"Good Clinical Practice\" are applicable, they should adhere to generally accepted good clinical practices including those set out in the current version of the Declaration of Helsinki and the International Conference on Harmonization Guidelines for Good Clinical Practice, FDA\u2019s most recent guidance and regulations concerning current Good Clinical Practice. However, MD Anderson's compliance with these standards may deviate from LBIO's instructions or its own internal policies and procedures where there is a conflict.\n(ii) The provisions of this Agreement (including each applicable Study Order and Protocol), and\n(iii) All written instruction from LBIO.",
    "contradiction_score": 0.009095216169953346,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 32,
    "start_char": 22792,
    "end_char": 23683,
    "original": "3.4 Patient Materials . \u201cPatient Materials \u201d shall mean those certain biological materials, and derivatives thereof and related patient data and information, received from individual patients and described in an applicable Materials Exhibit. Without limiting Section 3.3, MD Anderson shall further handle, transport, use and store Patient Materials exclusively at the Facility(ies) or otherwise in accordance with this Agreement, unless otherwise requested by LBIO in writing, and at all times strictly in accordance with (a) MD Anderson\u2019s standards of security and confidentiality and (b) all applicable privacy, security and data protection Laws (including the United States Health Insurance Portability and Accountability Act of 1996, as amended by the HITECH Act, including the Standards for Privacy of Individually Identifiable Health Information, and the EU Data Protection Directive).",
    "ollama_generated": "3.4 Patient Materials . \"Patient Materials\" shall denote the biological specimens, their derivatives, associated patient data, and pertinent information sourced from individual patients, as defined in the specified Materials Exhibit. In addition to Section 3.3 stipulations, LBIO grants MD Anderson discretionary authority for handling, transporting, utilizing, and storing Patient Materials, primarily at the Facility(ies), or as otherwise prescribed within this Agreement, unless explicitly directed otherwise in writing by MD Anderson. All such activities shall be performed strictly in adherence to (a) MD Anderson's standards of security and confidentiality, and (b) all applicable privacy, security, and data protection Laws, including but not limited to the United States Health Insurance Portability and Accountability Act of 1996, as amended by the HITECH Act, including the Standards for Privacy of Individually Identifiable Health Information, and the EU Data Protection Directive. The responsibility for ensuring compliance with these regulations shall rest upon MD Anderson.",
    "contradiction_score": 0.007370905950665474,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 34,
    "start_char": 23747,
    "end_char": 25270,
    "original": "4.1 Initial Funding . LBIO agrees to commit funding in an amount not to exceed $14,211,864.00 for the performance of the Studies during the Term (collectively, \u201c Initial Funding \u201d), with the Initial Funding specifically allocated as follows: (a) $[* * *] for an upfront payment, and a minimum of $[* * *] for enrollment and treatment of a minimum of 40 patients in the Study described in Exhibit I (i.e., the Minimum Enrollment Target as defined in Exhibit 1) or up to $[* * *] (an \u201c Individual Study Budget \u201d) for enrollment and treatment of up to 60 patients in the Study described in Exhibit I (i.e., the Maximum Enrollment Target as defined in Exhibit 1)\u037e (b) $[* * *] (which shall also be considered an Individual Study Budget ) for enrollment, manufacturing of product, and treatment of 30 patients in the Study described in Exhibit II\u037e and (c) $[* * *] for the Study described in Exhibit III. LBIO shall pay the Initial Funding in accordance with Section 4.3. For clarity, the Initial Funding is Collaboration Funding. MD Anderson agrees that all costs of this Collaboration, with the sole exceptions of any costs to supply clinical-grade aldesleukin and 4-1BB agonist for use in the expansion of tumor infiltrating lymphocytes (\u201c TILs \u201d), and in the case of aldesleukin, for use in the treatment of patients, are included in the Initial Funding. Subject to the foregoing exceptions, MD Anderson shall be solely responsible for any costs it incurs in performing the Studies that are in excess of the Initial Funding.",
    "ollama_generated": "4.1 Initial Funding Commitment: LBIO is not obligated to provide funding exceeding $14,211,864.00 for the duration of the Term (hereinafter \"Initial Funding\"), and shall allocate such funds as follows: (a) $[* * *] for an upfront payment, and a minimum of $[* * *] to cover expenses associated with enrolling and treating a minimum of 40 patients in the Study outlined in Exhibit I (referred to as the \"Minimum Enrollment Target\" as defined in Exhibit 1), or a maximum of $[* * *] for enrollment, treatment, and related costs for up to 60 patients in the same Study (herein referred to as the \"Maximum Enrollment Target\" as defined in Exhibit 1). The remaining Initial Funding will be allocated as follows: (b) $[* * *] for enrollment, product manufacturing, and treatment of 30 patients in the Study described in Exhibit II; and (c) $[* * *] for the Study described in Exhibit III. LBIO shall disburse the Initial Funding according to Section 4.3. For the sake of clarity, the Initial Funding constitutes Collaboration Funding. MD Anderson acknowledges that all expenses related to this Collaboration, with the exceptions of the costs associated with procuring clinical-grade aldesleukin and 4-1BB agonist for the expansion of tumor infiltrating lymphocytes (\"TILs\") and the treatment of patients (as it pertains to aldesleukin), are included within the Initial Funding. MD Anderson accepts responsibility for any costs incurred during the performance of the Studies that exceed the allocated Initial Funding, except as expressly provided herein.\n\nIn this revised clause, LBIO's obligation is weakened by stating that they are not obligated to provide more than $14,211,864 in funding, and the responsibility for costs exceeding the Initial Funding is shifted to MD Anderson. The allocation of funds for each study is also clarified, and the language has been adjusted to be more fluent and professional.",
    "contradiction_score": 0.045263368636369705,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 38,
    "start_char": 26442,
    "end_char": 27796,
    "original": "Milestone (on Study Order-by-Study Order basis) Payment (% of the Individual Study Budget) to be provided in connection with such Study Order * Enrollment of [* * *]% of the target patient enrollment as set forth in the applicable Protocol [* * *]% Enrollment of [* * *]% of the target patient enrollment as set forth in the applicable Protocol [* * *]% Enrollment of [* * *]% of the target patient enrollment as set forth in the applicable Protocol [* * *]% Enrollment of final patient as set forth in the applicable Protocol  [* * *]% Receipt by LBIO of both (a) the final clinical study report and (b) all raw clinical data (anonymized and without including any identifying information) [* * *]% *With respect to Exhibit 1, the Individual Study Budget shall be the one associated with the Minimum Enrollment Target (as defined in Exhibit 1), and in the event that the Parties move to the Maximum Enrollment Target (as defined in Exhibit 1) then this table shall be applied to the incremental additional patients as if the incremental additional patients constitute their own protocol/budget. For example, if LBIO decides to add ten (10) additional patients to the clinical study in Exhibit 1, each patient will be accrued at $[* * *] per patient, and LBIO will be invoiced for percentage enrollment of these ten (10) patients based on the table above.",
    "ollama_generated": "Milestone Payments (on a Study Order-by-Study Order basis) will be provided, contingent upon the following conditions:\n\n1. Completion of [* * *]% of the minimum required patient enrollment as outlined in the relevant Protocol.\n2. Subsequent completion of [* * *]% of the remaining patient enrollment (from the minimum to the maximum target) as set forth in the applicable Protocol.\n3. Enrollment of the final patient as stipulated in the applicable Protocol.\n4. Receipt by LBIO of both:\n   a. The final clinical study report, and\n   b. All raw clinical data (anonymized and without any identifying information).\n\nFor Exhibit 1, the Individual Study Budget will be that associated with the Maximum Enrollment Target (as defined in Exhibit 1), and if the Parties decide to reduce the enrollment target (down to the Minimum Enrollment Target as defined in Exhibit 1), the table will still apply proportionally to the reduced number of patients. For instance, if LBIO decides to decrease the number of patients in the clinical study outlined in Exhibit 1 by ten (10), each patient will be accrued at $[* * *], and LBIO will be billed for the percentage enrollment of these ten (10) patients based on the table above.",
    "contradiction_score": 0.3868309557437897,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 39,
    "start_char": 27796,
    "end_char": 27965,
    "original": "(b) In the event that the Study Order covers activities other than the performance of a clinical trial, a payment schedule will be set forth in the relevant Study Order.",
    "ollama_generated": "(b) If the scope of the Study Order encompasses activities not exclusively dedicated to conducting a clinical trial, it shall be incumbent upon the parties to establish a payment schedule as specified within the Study Order itself.",
    "contradiction_score": 0.0007072281441651285,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 53,
    "start_char": 35681,
    "end_char": 36341,
    "original": "(c) Neither Party shall improperly use or disclose to the other Party or any of its directors, officers, employees or agents, any confidential information of any current or former client or other person or entity with whom such Party has an agreement or duty to keep such information confidential, and such Party shall not bring onto the premises of the other Party any such information in any medium unless consented to in writing by such client, person or entity. In the event of a Party\u2019s breach of this Section 6.1(c), the breaching Party shall ensure that the other Party may freely and fully utilize the information so disclosed for any and all purposes.",
    "ollama_generated": "(c) Each Party acknowledges their obligation to preserve and protect, from unauthorized use or disclosure, any confidential information of current or former clients or any person or entity with whom they maintain a confidentiality agreement. This includes refraining from bringing such information onto the premises of the other Party without prior, written consent from the relevant client, person, or entity. Notwithstanding this obligation, in the event that one Party discloses confidential information in violation of this Section 6.1(c), the disclosing Party shall indemnify and hold harmless the receiving Party from any claims, damages, or liabilities arising from such disclosure, thus enabling unrestricted use of the disclosed information by the receiving Party for any purposes they deem necessary.",
    "contradiction_score": 0.17264296114444733,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 71,
    "start_char": 47262,
    "end_char": 48058,
    "original": "(c) As between the Parties, and without limiting MD Anderson\u2019s assistance obligations under Section 7.2(b), LBIO shall have the sole and exclusive right to file patents covering or claiming Inventions and shall bear all costs with respect to the prosecution and maintenance thereof. In furtherance of the foregoing, the Parties shall work together in good faith to, as expeditiously as possible following the Effective Date, put in place a power of attorney granted by the System to LBIO for purposes of enabling LBIO to apply for or to pursue any application for any United States or foreign patent, trademark, copyright or other registration covering Inventions or Works assigned to LBIO hereunder in the event that LBIO is unable to secure MD Anderson\u2019s assistance in connection with the same.",
    "ollama_generated": "(c) In relation to the Parties, and without restricting MD Anderson's assistance obligations as outlined in Section 7.2(b), LBIO shall hold the sole and exclusive authority to file patents related to or encompassing Inventions, and will shoulder all expenses associated with their prosecution and maintenance. To achieve this aim, the Parties will collaborate diligently, with promptness after the Effective Date, to establish a power of attorney from the System to LBIO, enabling LBIO to apply for or pursue any application for United States or foreign patent, trademark, copyright, or other registration covering Inventions or Works assigned to LBIO hereunder. In instances where LBIO encounters difficulty in obtaining MD Anderson's assistance with regards to the aforementioned registrations, it will be understood that MD Anderson shall provide such assistance at the request of LBIO.\n\nThis revised clause aims to make it clear that while LBIO has the primary responsibility for patenting inventions, they may seek MD Anderson's assistance if necessary, rather than specifying a scenario where MD Anderson might proactively assist with patents.",
    "contradiction_score": 0.007083442062139511,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 89,
    "start_char": 55881,
    "end_char": 56600,
    "original": "(b) Neither MD Anderson nor any of its Representatives have (i) violated or caused a violation of any federal or state health care fraud and abuse or false claims statute or regulation, including the anti-kickback provisions of the Social Security Act, 42 U.S.C. \u00a7 1320a-7b(b), (ii) violated or caused a violation of any federal or state privacy or security law or regulation, including HIPAA, (iii) not been excluded or threatened with exclusion under state or federal statutes or regulations, including under 42 U.S.C. \u00a7 1320a-7 or relevant regulations in 42 C.F.R. Part 1001, or (iv) not been assessed or threatened with assessment of civil money penalties pursuant to 42 C.F.R. Part 1003, or any foreign equivalent.",
    "ollama_generated": "(b) MD Anderson and its Representatives affirm that:\n\n(i) They have not knowingly engaged in, nor contributed to, any violations of federal or state health care fraud and abuse or false claims statutes or regulations, including the anti-kickback provisions of the Social Security Act, 42 U.S.C. \u00a7 1320a-7b(b).\n\n(ii) They have complied with all applicable federal and state privacy or security laws and regulations, including HIPAA, to the best of their knowledge. Any inadvertent noncompliance will be promptly addressed upon discovery and corrected as required by law.\n\n(iii) There is no current exclusion order against them under state or federal statutes or regulations, including under 42 U.S.C. \u00a7 1320a-7 or relevant regulations in 42 C.F.R. Part 1001. However, they acknowledge that potential future exclusions may occur as a result of investigations, audits, or other proceedings.\n\n(iv) They have not been assessed any civil money penalties pursuant to 42 C.F.R. Part 1003, or any foreign equivalent. If they become aware of any potential assessment, they will immediately disclose this information and take appropriate corrective action.",
    "contradiction_score": 0.07788257300853729,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 91,
    "start_char": 56870,
    "end_char": 58246,
    "original": "(d) Neither MD Anderson nor any of its Representatives (i) have been found by the FDA or any other relevant governmental or regulatory authority to have violated any Laws, regulations or guidelines concerning the conduct of clinical investigations or related services\u037e (ii) have been debarred, denied, or suspended by the FDA under 21 U.S.C. \u00a7 335a, disqualified or restricted by the FDA, named on any FDA list related to investigator disqualifications, restrictions, restrictions removed, or adequate assurances, or are otherwise ineligible to participate in federal procurement or non-procurement programs or any foreign equivalents of the above\u037e and (iii) have any unresolved FDA warning letter, Form 483, or other regulatory enforcement action threatened against or issued to them\u037e (e) MD Anderson and its Representatives will not make and have not made any untrue statement of material fact to or filed a false claim or report with any governmental or regulatory authority, or failed to disclose a material fact required to be disclosed to any governmental or regulatory authority, or have ever been investigated by the FDA, National Institutes of Health (\u201c NIH\u201d), Office of the Inspector General for the Department of Health and Human Services (\u201c OIG\u201d), Department of Justice or other comparable governmental or regulatory authority for data or healthcare program fraud.",
    "ollama_generated": "(d) It is not admitted nor has it been established, to the knowledge of MD Anderson or any of its Representatives, that they have violated any Laws, regulations, or guidelines pertaining to the conduct of clinical investigations or related services, as determined by the FDA or any other relevant governmental or regulatory body. Further, no sanctions such as debarment, denial, suspension, disqualification, restriction, or addition to any list related to investigator disqualifications, restrictions, or ineligibility for participation in federal procurement or non-procurement programs, or their foreign counterparts have been imposed on them. However, it is not guaranteed that no unresolved FDA warning letter, Form 483, or other regulatory enforcement action may be threatened against or issued to them in the future. (e) MD Anderson and its Representatives are under no suspicion of making any materially false statement, filing a falsified claim or report, failing to disclose a required material fact, or being investigated for data or healthcare program fraud by the FDA, NIH, OIG, Department of Justice, or other comparable governmental or regulatory authority.",
    "contradiction_score": 0.025694869458675385,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 99,
    "start_char": 61128,
    "end_char": 61871,
    "original": "9.4 Independent Status . MD Anderson shall not be considered a partner, co-venturer, agent, employee, or representative of LBIO by reason of this Agreement, but shall remain in all respects an independent contractor, and neither Party shall have any right or authority to make or undertake any promise, warranty or representation, to execute any contract or otherwise to assume any obligation in the name of or on behalf of the other Party. MD Anderson\u2019s employees, including the Principal Investigator and the other Representatives of MD Anderson, are not and shall not be deemed to be employees of LBIO, and MD Anderson shall indemnify and hold harmless LBIO from all liabilities arising from any allegation or determination to the contrary.",
    "ollama_generated": "9.4 Independent Operational Role: LBIO will not recognize nor assume any partnership, co-venture, agency, employment, or representative relationship with MD Anderson based on this Agreement. Instead, MD Anderson shall continue to function as an independent entity, and neither party shall possess the power to commit to any promise, warranty, representation, contract, or obligation using the other party's name or authority. Any employees of MD Anderson, including the Principal Investigator and other designated representatives, will not be considered employees of LBIO. In the event that any liabilities arise due to claims or determinations suggesting otherwise, MD Anderson shall provide indemnification and protection from harm for LBIO.\n\nThis revised clause retains a professional tone while emphasizing the independent status of both parties and assigning responsibility for potential liabilities to MD Anderson.",
    "contradiction_score": 0.005281717050820589,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 101,
    "start_char": 62444,
    "end_char": 62479,
    "original": "If to LBIO, to:  If to MD Anderson:",
    "modified": "In the event that LBIO is the recipient (hereinafter \"LBIO\"), then: In the event that MD Anderson is the recipient (hereinafter \"MDA\"), alternatively:\n\nThe obligations and responsibilities set forth herein shall be fulfilled by both parties. If, however, MDA is the party receiving these terms and conditions, LBIO shall have no obligation or responsibility to comply with any of the provisions stated in this agreement, except as expressly provided otherwise. Instead, all rights, duties, and liabilities arising under this contract shall be solely vested in MDA.\n\nIn other words, if LBIO is the recipient, both parties are bound by the terms and obligations. Conversely, if MDA is the recipient, LBIO is exempted from fulfilling any obligations or responsibilities unless specified otherwise, and all rights, duties, and liabilities are exclusively assigned to MDA.",
    "contradiction_score": 0.7445505857467651,
    "kept": true
  },
  {
    "clause_index": 105,
    "start_char": 64445,
    "end_char": 65132,
    "original": "9.8 Equitable Relief . MD Anderson agrees that it may be impossible or inadequate to measure and calculate LBIO\u2019s damages from any breach of MD Anderson\u2019s obligations under Section 6 and/or Section 7 of this Agreement, and that a breach of such obligations could cause serious and irreparable injury to LBIO. Accordingly, LBIO shall have available, in addition to any other right or remedy available to it, the right to seek an injunction from a court of competent jurisdiction restraining such a breach (or threatened breach) and to specific performance of any such Section. MD Anderson further agrees that no bond or other security shall be required in obtaining such equitable relief.",
    "ollama_generated": "9.8. Equitable Remedies Granted to LBIO. LBIO acknowledges that in the event of a breach by LBIO of MD Anderson's obligations as outlined in Sections 6 and/or 7 of this Agreement, such breach could potentially cause significant and irreversible harm to MD Anderson. Consequently, MD Anderson shall have the right, in addition to any other legal recourse it may pursue, to seek an injunction from a competent court restraining such a breach (or impending breach) and enforcing compliance with the relevant Section of this Agreement. Furthermore, MD Anderson agrees that no bond or other form of security will be required for obtaining such equitable relief.",
    "contradiction_score": 0.005789483897387981,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 111,
    "start_char": 67053,
    "end_char": 67322,
    "original": "9.14 Texas State Agency . MD Anderson is an agency of the State of Texas and under the constitution and laws of the State of Texas possesses certain rights and privileges and only such authority as is granted to it under the constitution and laws of the State of Texas.",
    "ollama_generated": "9.14 MD Anderson as a State Agency: It is recognized that MD Anderson, as an agency of the State of Texas, operates under the constitutional and legal framework of said state, retaining only such powers and privileges explicitly granted by the same. Any authorities not expressly conferred are deemed not to be vested in this entity.",
    "contradiction_score": 0.001317690941505134,
    "kept": false,
    "reason": "low_contradiction"
  }
]